Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.

Jiayong LiuTian GaoZhichao TanShu LiJie XuChujie BaiRuifeng XueLu XieLu ZhangZhengfu FanWei Guo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The study showed the promising activity in patients with ASPS, also indicating the trend of treatment efficacy in other sarcomas. The toxicity was tolerable. More studies with larger sample size and controlled arm were warranted.

Keyphrases

phase ii study
locally advanced
squamous cell carcinoma
rectal cancer
neoadjuvant chemotherapy
open label
radiation therapy
small cell lung cancer
oxidative stress
randomized controlled trial
clinical trial
placebo controlled
case control
study protocol
combination therapy